RK-287107

• CAT Number: I019301
• CAS Number: 2171386-10-8
• Molecular Formula: C₂₂H₂₆F₂N₄O₂
• Molecular Weight: 416.46
• Purity: ≥95%
• Target: Epigenetics
• IUPAC Name: 2-[4,6-difluoro-1-(2-hydroxyethyl)spiro[2H-indole-3,4'-piperidine]-1'-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
• InChI: InChI=1S/C22H26F2N4O2/c23-14-11-16(24)19-18(12-14)28(9-10-29)13-22(19)5-7-27(8-6-22)21-25-17-4-2-1-3-15(17)20(30)26-21/h11-12,29H,1-10,13H2,(H,25,26,30)
• InChIKey: FZQYCOUBRJEYBC-UHFFFAOYSA-N
• SMILES: C1CCC2=C(C1)C(=O)NC(=N2)N3CCC4(CC3)CN(C5=C4C(=CC(=C5)F)F)CCO

RK-287107（Cat No.:I019301）is a small molecule inhibitor that targets the protein kinase AKT, which plays a crucial role in regulating cell growth, survival, and metabolism. AKT is often dysregulated in various cancers, contributing to tumor progression and resistance to chemotherapy. By inhibiting AKT, RK-287107 aims to disrupt key signaling pathways involved in cancer cell proliferation and survival, making it a potential therapeutic agent for cancer treatment. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth in certain cancer models, and ongoing research is focused on its safety, potency, and clinical applications in oncology.

Reference

[1]. Mizutani A, et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 2018 Dec;109(12):4003-4014.